Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI318 + cTACE for Potentially Resected Hepatocellular Carcinoma
NCT04635527Phase 1Terminated
- Sponsor
- Innovent Biologics
- Start
- Dec 2020
- Primary completion
- Aug 2021
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing IBI318 + cTACE with Placebo + cTACE (2 arms). Primary endpoint: Number of participants experiencing clinical and laboratory adverse events (AEs). Started Dec 2020; status: terminated.
02
Drugs
reozalimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04635527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04635527.